Developments in hepatitis C therapy during 2000 – 2002

Bibliography

• ALTER MJ, KRUSZON-MORAN D, NAINAN OV et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl. J. Med. (1999) 341:556–562.
   PubMed Web of Science ®Google Scholar
• ••A very good description of theepidemiology of HCV.
   Google Scholar
• DI BISCELGLIE AM: Natural history of hepatitis C: its impact on clinical management. Hepatology (2000) 31:1014–1018.
   PubMed Web of Science ®Google Scholar
• MCHUTCHINSON JG, GORDON SC, EUGENE E et al: Interferon alfa-26 alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl. J. Med. (1998) 335:1485–1492.
   Google Scholar
• FRIED MW, SHIFFMAN ML, REDDY R. et al.: Peg interferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl. J. Med. (2002) 347:975–982.
   PubMed Web of Science ®Google Scholar
• ••A landmark trial of PEG-IFN-a2
   Google Scholar
• MANNS MP, MCHUTCHISON JG, GORDON SC et al: Peginterferon alfa-26 plus ribavirin compared with interferon alfa-26 for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358(9286):958–965.
   PubMed Web of Science ®Google Scholar
• ••A landmark trial of PEG-IFN-a2b.
   Google Scholar
• ZEUZEM S, FEINMAN SV, RASENACK J et al.: Evaluation of the safety and efficacy of once weekly PEG/ interferon alfa-2a (Pegasys) for chronic hepatitis C. A multinational, randomized study. J. Hepatol. (2000) 32\(Suppl. 2):29.
   Google Scholar
• GLUE P, FANG JW, ROUZIER-PANI R et al.: Pegylated interferon alpha 2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. (2000) 68(5):556–567.
   PubMed Web of Science ®Google Scholar
• •A good description of the kinetics of PEG-IFN.
   Google Scholar
• HADZIYANNIS SJ, CHEINQUER H, MORGAN T et al: Peg interferon alfa-2a (40Kd) (Pegasys) in combination with ribavirin: efficacy and safety results from a Phase III, randomized double-blind, multicentre study examining effect of duration of treatment and ribavirin dose. Hepatol. (2002) 36\(Suppl. 1):1.
   Web of Science ®Google Scholar
• SAUNIER B, TRIYATNI M, ULIANICH L, MARUVADA P, YEN P, KOHN LD: Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. Virol. (2003) 77(1):546–559.
   Web of Science ®Google Scholar
• BILLICH A: Thymosin alphal, SciClone Pharmaceuticals. Carr. Opin. Investig. Drugs (2002) 3(5):698–707.
   PubMedGoogle Scholar
• ANDERSON KS: The molecular basis of inhibition and toxicity of modified cytosine analogues targeting HIV-1 reverse transcriptase. Antivirus Chem. Chemothec (2001) 12(Suppl. Y)1:13–17.
   Google Scholar
• GRACE JD, CAMERON CE: Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology (2002) 298(2):175–180.
   PubMed Web of Science ®Google Scholar
• CORRITORI S, LAU JY, LIN C: Safety studies of levovirin, a second generation ribavirin candidate, showed excellent safety profile. Hepatology (2001) 34(4):219A.
   Google Scholar
• VON WEIZSACKER F, WEILAND S, KOCK J et al.: Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides and dominant negative mutants. Hepatology (1996) 26:251–255.
   Google Scholar
• BARTENSCHLAGER R: Molecular targets in inhibition of hepatitis C virus replication. Antiviral Chem. Chemother: (1997) 8:281–302.
   Web of Science ®Google Scholar
• •A good review of targets for drug development.
   Google Scholar
• LEHMANN TJ, SERWE M, CASELMANN WH, ENGELS JW: Design and properties of hepatitis C virus antisense oligonucleotides for liver specific drug targeting. Nucleosides Nucleotides Nucleic Acids (2001) 20(4-7):1343–1346.
   PubMed Web of Science ®Google Scholar
• ZHANG H, HANECAK R, BROWN-DRIVER V et al.: Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob. Agents Chemother: (1999) 43(2):347–353.
   PubMed Web of Science ®Google Scholar
• WITHERELL GW: ISIS 14803 (Isis Pharmaceuticals). Curr. Opin. Investig. Drugs (2001) 11: 1523–1529.
   Google Scholar
• KWOH TJ, YU RZ, GEARY RS et al: Clinical pharmacokinetics of ISIS 14803, an antisense inhibitor of HCV, in patients with chronic HCV and comparison to non-clinical pharmacokineticshoxicology in monkeys. Hepatology (2001) 34(4):331A.
   Google Scholar
• OSTERWALDER T, YOON KS, WHITE BH, KESHISHIAN H: A conditional tissue-specific transgene expression system using inducible GAL4.Proc. Natl. Acad. Sci. USA (2001) 98(22):12596–12601.
   PubMed Web of Science ®Google Scholar
• ROMAN G, ENDO K, ZONG L, DAVIS RL: P [Switch], a system for spatial and temporal control of gene expression in Drosophila melanogaster. Proc. Natl. Acad. Sci. USA (2001) 98(22):12602–12607.
   PubMed Web of Science ®Google Scholar
• KRUEGER M, BEGER C, WELCH PJ, BARBER JR, MANNS MP, WONG-STAAL F: Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation. Mol. Cell. Biol. (2001) 21(24):8357–8364.
   PubMed Web of Science ®Google Scholar
• DAVIES K: Ribozyme technology. Cech wins first patent. Nature (1991) 349(6309)449.
   Google Scholar
• WELSH PJ, YEI S, BARBER JR: Ribozyme gene therapy for hepatitis C virus infection. Clin. Diagn. Virol. (1998) 10:163–171.
   PubMedGoogle Scholar
• PLEY HW, FLAHERTY KM, MCKAY DB: Three-dimensional structure of a hammerhead ribozyme. Nature (1994) 372:68–74.
   PubMed Web of Science ®Google Scholar
• MACEJAK DG, JENSEN KL, JAMISON SF et al.: Inhibition of hepatitis C virus (HCV-)RNA dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology (2000) 31(3):769–776.
   PubMed Web of Science ®Google Scholar
• TESSMANN K, ERHARDT A, HAUSSINGER D, HEINTGES T: Cloning and molecular characterization of human high affinity antibody fragments against Hepatitis C virus N53 helicase. Virol. Methods (2002) 103(1):75–88.
   PubMed Web of Science ®Google Scholar
• LOCATELLI GA, GOSSELIN G, SPADARI S, MAGA G: Hepatitis C virus N53 NTPase/helicase: different stereoselectivity in nucleoside triphosphate utilization suggests that NTPase and helicase activities are coupled by a nucleotide-dependent rate limiting step. J. Ma Biol. (2001) 313(4):683–694.
   Web of Science ®Google Scholar
• HEINTGES T, ENCKE J, ZU PUTLITZ J, WANDS JR: Inhibition of hepatitis C virus N53 function by antisense oligodeoxynucleotides and protease inhibitor. J. Med. Virol. (2001) 65(4):671–680.
   PubMed Web of Science ®Google Scholar
• •A good description of NS3 function of HCV.
   Google Scholar
• MCHUTCHISON JG, CHEUNG R, SHIFFMAN M et al.: A 4 week trial of VX 497 (an IMPDH inhibitor) combined with interferon in previously untreated patients with chronic hepatitis C. Hepatology (2001) 34(2):329A. 31.HELBLING B, STAMENIC I, VIANI F et al.: Interferon and amantiadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology (2002) 35(2):447–454.
   Web of Science ®Google Scholar
• HELBLING B, STAMENIC I, VIANIF et al.: Interferon and amantiadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology (2002) 35(2):447–454.
   PubMed Web of Science ®Google Scholar
• MERCER DF, SCHILLER DE, ELLIOTT JF et al.: Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. (2001) 7(8):927–933.
   PubMed Web of Science ®Google Scholar
• ••An important paper of HCV replication ina mouse model.
   Google Scholar
• LECHMANN M, MURATA K, SATOI J et al.: Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology (2001) 34(2):417–423.
   PubMed Web of Science ®Google Scholar
• BRINSTER C, MUGUET S, LONE YC et al.: Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology (2001) 34(6):1206–1217.
   PubMed Web of Science ®Google Scholar
• HUNZIKER IP, ZURBRIGGEN R, GLUECK R et al: Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol. (2001) 38(6):475–484.
   PubMed Web of Science ®Google Scholar
• HEVEY M, NEGLEY D, VAN DER ZANDEN L et al.: Marburg virus vaccines: comparing classical and new approaches. Vaccine (2001) 12(3-0586–593.
   Google Scholar
• DOCKRELL DH, KINGHORN GR: Imiquimod and resiquimod as novel immunomodulators. Antimicrob. Chemother. (2001) 48(6):751–755.
   Web of Science ®Google Scholar
• O'BRIEN CB, MOONKA DK, HENZEL BS et al: A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon alpha. Am. Gastroenterol. (2001) 96(8):2473.
   PubMed Web of Science ®Google Scholar
• TAO SH, BOLGER PM, REGUL R: Hazard assessment of germanium supplements. Reg. Toxicol. & Pharmacol. (1997) 25(3):211–219.
   PubMed Web of Science ®Google Scholar